missing translation for 'onlineSavingsMsg'
Learn More
Learn More
CD279 (PD-1) Monoclonal Antibody (RMP1-14), Functional Grade, eBioscience™, Invitrogen™
Rat Monoclonal Antibody
Marque: Affymetrix eBioscience 16-9982-025
Les retours ne sont pas autorisés pour ce produit.
Afficher la politique du retour.
Description
This antibody reacts with mouse PD-1 (programmed death-1), a 55 kDa member of the Ig superfamily. PD-1 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) and plays a key role in peripheral tolerance and autoimmune disease in mice. PD-1 is expressed mainly on activated T and B lymphocytes. Two novel B7 Family members have been identified as PD-1 ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC). Evidence reported to date suggests overlapping functions for these ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Similar to J43, another mAb to mouse PD-1 (Cat. No. 16-9985), RMP1-14 blocks the binding of both B7-H1-Ig and B7-DC-Ig to PD-1 transfectants.
CD279 (PD-1) Monoclonal antibody specifically detects CD279 (PD-1) in Mouse samples. It is validated for Flow Cytometry, Functional Assay
Spécification
| CD279 (PD-1) | |
| Monoclonal | |
| 1 mg/mL | |
| PBS with no preservative; pH 7.2 | |
| Q02242 | |
| Rat | |
| 25 mg | |
| Primary | |
| Mouse | |
| Antibody | |
| IgG2a κ |
| Flow Cytometry, Functional Assay | |
| RMP1-14 | |
| Functional Grade | |
| Pdcd1 | |
| CD279; EGK_05005; hPD1; hPD-1; hPD-l; hSLE1; Ly101; mPD-1; PD1; PD-1; Pdc1; Pdcd1; programmed cell death 1; programmed cell death 1 protein; programmed cell death protein 1; programmed cell death protein 1-like; programmed death 1; Protein PD1; Protein PD-1; sCD279; SLEB2; soluble CD279; systemic lupus erythematosus susceptibility 2 | |
| Affinity chromatography | |
| RUO | |
| 18566 | |
| 4° C | |
| Liquid |
Correction du contenu d'un produit
Veuillez fournir vos retours sur le contenu du produit en remplissant le formulaire ci-dessous.
Nom du produit
Vous avez repéré une opportunité d'amélioration ?Partager une correction de contenu